Ask about this productRelated genes to: Fscn1 Blocking Peptide
- Gene:
- FSCN1 NIH gene
- Name:
- fascin actin-bundling protein 1
- Previous symbol:
- SNL
- Synonyms:
- p55, FLJ38511
- Chromosome:
- 7p22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1995-01-16
- Date modifiied:
- 2016-10-05
Related products to: Fscn1 Blocking Peptide
Related articles to: Fscn1 Blocking Peptide
- Fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA) synovium acquire a unique aggressive phenotype and produce cytokines that perpetuate inflammation and proteases that contribute to cartilage destruction. Actin bundling protein Fascin-1 (FSCN1) is involved in FLS migration and invasion, but its role and mechanism in FLS phenotypic activation remain unclear. - Source: PubMed
Publication date: 2026/08/17
Chen LiangyuWu JunfengZhou TaoZou ZilinCheng QinweiChen DalinLi HonghaoYang PanpanYang ChengliangWang HongLi Kai - Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that the Transwell migration and invasion assay experiments shown in Figs. 3D, 6D and F, and 7G and I contained three sets of overlapping sections of data, such that data which were intended to show the results of differently performed experiments had apparently been derived from the same original sources. In addition, the 'si‑FSCN1' data panel for the migration assay experiments shown in Fig. 6D apparently reappeared in Fig. 6 of another paper written by different authors at different research institutes, which was submitted at a later date to the journal . The authors have been contacted by the Editorial Office to offer an explanation for the apparent anomalies in the presentation of the data in this paper, and we are awaiting their response. Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of this potential problem while the Editorial Office continues to investigate this matter further. [Molecular Medicine Reports 22: 5282‑5292, 2020; DOI: 10.3892/mmr.2020.11592]. - Source: PubMed
Publication date: 2026/08/14
He ShufangYu GuiyuanPeng KeLiu Sisun - Colorectal cancer liver metastasis (CRLM) remains a major clinical challenge. Xian-Lian-Jie-Du Decoction (XLJDD) has shown anti-tumor activity against colorectal cancer, but its mechanism in CRLM remains unclear. - Source: PubMed
Publication date: 2026/06/23
Zhang QinchangShi ZeanbangQian JingyangGeng XuechenTao YuquanDong DanShi HewenZhang DongSun YangCheng Haibo - Although fibroblast growth factor receptor (FGFR) inhibitors (FGFRi) have demonstrated clinical promise, the inevitable emergence of acquired resistance remains a critical bottleneck, severely compromising their long-term clinical efficacy. The pan-cancer molecular landscape and heterogeneous mechanisms driving this resistance, ranging from genetic alterations to dynamic network rewiring, remain poorly understood. - Source: PubMed
Publication date: 2026/06/25
Tan LinghuiHou TianlunYing PingtingWang XianJin HongchuanLuo Jingfeng - Currently, a systematic explanation of the clinical application and diagnostic value of Fascin-1 (FSCN1) in lung cancer has not been established. This study used immunohistochemistry (IHC) to detect the expression level of FSCN1 protein in 276 cases of non-small cell lung cancer (NSCLC) tissues, to explore the clinical value of FSCN1 and its diagnostic value in distinguishing between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). FSCN1 expression was analyzed in normal lung tissues, LUAD, and LUSC. The positivity rates were 0.0% (0/41) in normal tissues, 50.9% (85/167) in LUAD, and 98.2% (107/109) in LUSC. Furthermore, strong positivity was observed in 0.0% (0/41), 19.8% (33/167), and 93.6% (102/109) of these tissue groups, respectively. Both the overall positivity and the strong positivity rates of FSCN1 were significantly higher in LUSC than in either LUAD or normal lung tissues. ROC curve analysis demonstrated that FSCN1 positivity and strong positivity effectively discriminated LUSC, with areas under the curve (AUC) of 0.736 (95% CI: 0.679-0.794; P < 0.001) and 0.869 (95% CI: 0.824-0.914; P < 0.001), respectively. In LUAD, FSCN1 positive expression was significantly associated with male gender, tumor size >3 cm, poor differentiation, lymph node metastasis, and higher tumor stage. Similarly, FSCN1 strong positive expression was associated with male gender, tumor size >3 cm, poor differentiation, and smoking history. Multiple logistic regression analysis identified that independent predictors of FSCN1 positive expression in LUAD included poorly differentiated tumors (OR = 2.576; 95% CI: 1.085-6.114; P = 0.032) and higher tumor stage (OR = 2.316; 95% CI: 1.205-4.453; P = 0.012). Meanwhile, independent predictors of FSCN1 strong positive expression included male gender (OR = 3.036; 95% CI: 1.376-6.700; P = 0.006). Survival analysis revealed that FSCN1 positivity was significantly associated with reduced 5-year relapse-free survival (RFS) in LUAD patients (P = 0.025), though no significant association was observed with overall survival (OS). These findings indicate that FSCN1 may play an important role in lung cancer pathogenesis and progression, and could serve as a differential diagnostic marker between LUSC and LUAD. - Source: PubMed
Publication date: 2026/06/08
Wang YanLu Shi-PingJiang Li-JingShao Jun-KangDu Zhi-QunLu Hua-JunHuang Bi-FeiWang Chao-Qun